Filana Therapeutics, Inc. Increase (Decrease) in Other Operating Liabilities
Filana Therapeutics, Inc. (FLNA) reported Increase (Decrease) in Other Operating Liabilities of -$130.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingLiabilities · last filed 2026-05-07
- Filana Therapeutics, Inc. increase (decrease) in other operating liabilities for the quarter ending 2026-03-31 was -$130.00K.
- Filana Therapeutics, Inc. increase (decrease) in other operating liabilities for the quarter ending 2025-12-31 was -$29.00K, a 3000.00% decline year-over-year.
- Filana Therapeutics, Inc. increase (decrease) in other operating liabilities for the quarter ending 2025-09-30 was $107.00K, a 28.19% decline year-over-year.
- Filana Therapeutics, Inc. increase (decrease) in other operating liabilities for the quarter ending 2025-06-30 was $46.00K, a 55.34% decline year-over-year.
- Filana Therapeutics, Inc. increase (decrease) in other operating liabilities for fiscal 2025 was -$62.00K.
- Filana Therapeutics, Inc. increase (decrease) in other operating liabilities for fiscal 2024 was -$7.00K.
- Filana Therapeutics, Inc. increase (decrease) in other operating liabilities for fiscal 2023 was -$304.00K.
- Filana Therapeutics, Inc. increase (decrease) in other operating liabilities for fiscal 2022 was -$136.00K, a 118.60% decline from fiscal 2021.
| Period end | Increase (Decrease) in Other Operating Liabilities 3 month | Increase (Decrease) in Other Operating Liabilities 6 month | Increase (Decrease) in Other Operating Liabilities 9 month | Increase (Decrease) in Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-03-31 | -$130.00K 10-Q · filed 2026-05-07 | -$159.00K derived: sum of 2 quarters · filed 2026-05-07 | -$52.00K derived: sum of 3 quarters · filed 2026-05-07 | -$6.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | -$29.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $78.00K derived: sum of 2 quarters · filed 2026-03-12 | $124.00K derived: sum of 3 quarters · filed 2026-03-12 | -$62.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | $107.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $153.00K derived: sum of 2 quarters · filed 2025-11-12 | -$33.00K 10-Q · filed 2025-11-12 | -$32.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-06-30 | $46.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$140.00K 10-Q · filed 2025-08-14 | -$139.00K derived: sum of 3 quarters · filed 2026-05-07 | $10.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-03-31 | -$186.00K 10-Q · filed 2026-05-07 | -$185.00K derived: sum of 2 quarters · filed 2026-05-07 | -$36.00K derived: sum of 3 quarters · filed 2026-05-07 | $67.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $150.00K derived: sum of 2 quarters · filed 2026-03-12 | $253.00K derived: sum of 3 quarters · filed 2026-03-12 | -$7.00K 10-K · filed 2026-03-12 |
| 2024-09-30 | $149.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $252.00K derived: sum of 2 quarters · filed 2025-11-12 | -$8.00K 10-Q · filed 2025-11-12 | -$14.00K derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-06-30 | $103.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$157.00K 10-Q · filed 2025-08-14 | -$163.00K derived: sum of 3 quarters · filed 2026-03-12 | -$65.00K derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-03-31 | -$260.00K 10-Q · filed 2025-05-08 | -$266.00K derived: sum of 2 quarters · filed 2026-03-12 | -$168.00K derived: sum of 3 quarters · filed 2026-03-12 | -$251.00K derived: sum of 4 quarters · filed 2026-03-12 |
| 2023-12-31 | -$6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $92.00K derived: sum of 2 quarters · filed 2026-03-12 | $9.00K derived: sum of 3 quarters · filed 2026-03-12 | -$304.00K 10-K · filed 2026-03-12 |
| 2023-09-30 | $98.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $15.00K derived: sum of 2 quarters · filed 2024-11-07 | -$298.00K 10-Q · filed 2024-11-07 | -$222.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | -$83.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$396.00K 10-Q · filed 2024-08-08 | -$320.00K derived: sum of 3 quarters · filed 2025-03-03 | |
| 2023-03-31 | -$313.00K 10-Q · filed 2024-05-10 | -$237.00K derived: sum of 2 quarters · filed 2025-03-03 | ||
| 2022-12-31 | $76.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$136.00K 10-K · filed 2025-03-03 | ||
| 2022-09-30 | -$212.00K 10-Q · filed 2023-11-07 | |||
| 2021-12-31 | $731.00K 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |